Effects of a Supplement Containing Fucoidan on Basal Body Temperature

Hiroshima University19 enrolled

Overview

We aim to determine whether a supplement containing fucoidan isolated from Mekabu (sporophyll of Undaria pinnatifida), EPA, and DHA has effects of elevating basal body temperature in subjects with low basal body temperature.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

Conditions

Low Basal Body Temperature

Interventions

Supplement containing fucoidan, EPA, and DHADIETARY_SUPPLEMENT

75 mg fucoidan per day, for 8 weeks

PlaceboDIETARY_SUPPLEMENT

for 8 weeks

Eligibility

Sex: FEMALEMin age: 55 YearsMax age: 70 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Postmenopausal women with basal body temperature \< 36.0 ºC * Healthy as based on medical history and physical examination * Willing not to donate blood during the study * Informed consent signed Exclusion Criteria: * Renal or hepatic dysfunction * Heart disease * Participation in any clinical trial within 90 days of the commencement of the trial * Subjects who are taking medicines or functional food that may affect basal body temperature

Locations (1)

Hiroshima University

Hiroshima, Japan

Outcomes

Primary Outcomes

Basal body temperature

Time frame: up to 20 weeks

Secondary Outcomes

Change from baseline in serum lipid levels (total cholesterol, LDL cholesterol, HDL cholesterol, and triglyceride)

Time frame: Weeks 0, 8, 12, and 20

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.